Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR A new target to slow down ageing and reduce blood cancer... June 29, 2023 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients... January 15, 2021 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS What’s Your Mantra? FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology... Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer
